AbstractObjective: To analyze the expression of FOSB in acute myeloid leukemia （AML） and its correlation with prognosis of the patient based on the large sample data.
Methods: The genome, transcriptome, gene chip and clinical information from multiple public databases were statistical analyzed.
Results: The expression of FOSB gene in AML patients was significantly higher than that in normal people. The prognostic analysis of the 163 patients showed that the patients with high FOSB expression showed longer OS and EFS than those with FOSB low expression. The patients were further divided into chemotherapy group and allogeneic hematopoietic stem cell transplantation (allo-HSCT) group according to the treatment method, and then each group was divided into two subgroups (FOSBhigh, FOSBlow) according to the median expression level of FOSB. In the allo-HSCT group, the patients with FOSB high expression was longer event-free survival (EFS: P=0.017) and overall survival (OS: P=0029). At the same time, allo-HSCT in patients with high FOSB expression could improve the prognosis of the patients (Chemotherapy vs Allo-HSCT, OS: P<0.001, EFS: P=0.007). Multivariate analysis showed that the high expression of FOSB was an independent favorable prognostic factor for EFS and OS (EFS: HR=0.501， P=0.019; OS: HR=0.461， P=0.009) of the patients.
Conclusion: The high expression of FOSB indicated a good prognosis for acute myeloid leukemia.
题目: FOSB基因在急性髓系白血病中的预后价值.
目的: 基于大样本数据分析FOSB表达量与急性髓系白血病患者预后的关系.
方法: 对多个公共数据库中基因组、转录组、基因芯片及临床信息进行统计分析.
结果: 急性髓系白血病患者FOSB基因表达量较健康人明显升高。163例急性髓系白血病患者预后分析提示，FOSB高表达患者表现出更长的OS及EFS（P=0.02，P=0035）。根据治疗方式进一步将患者分为化疗组和异基因造血干细胞移植组，每组根据FOSB的表达水平中位值再分为FOSB高表达、FOSB低表达组，并进行生存分析。在移植组中，FOSB高表达患者较低表达患者有更长的无事件生存期（EFS：P=0.017）和总生存期（OS：P=0.029）。同时在163例患者中，FOSB高表达组患者进行异基因造血干细胞移植可提高该类患者预后（Chemotherapy vs Allo-HSCT， OS：P<0.001， EFS：P=0.007）。多因素分析表明，FOSB高表达是EFS和OS的独立有利预后因素（EFS：HR=0.501，P=0.019；OS：HR=0.461，P=0.009）.
结论: FOSB的高表达提示急性髓系白血病患者良好的预后.
Keywords: FOSB; acute myeloid leukemia; prognosis.